Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 4.6% from a year ago

Cash & equivalents stood at $9.64M at the end of Q1 FY2026, down 4.6% from a year earlier and down 48.2% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Cash & equivalents amounted to 18.6% of total assets at the end of Q1 FY2026, down 23.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -4.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.64M-48.2% QoQ
Last fiscal yearDec 2025
$18.62M+394.9% YoY
Year agoMar 2025
$10.11M-4.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.6%——
1 year+394.9%——
3-year CAGR-11.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
18.62M USD
Year-over-year change
+394.9%
4-year CAGR
-36.9%

Cash & Equivalents vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -4.6% is the 6th highest of 9, against a peer median of +3.0%.
  • Cash & equivalents amounts to 18.6% of total assets for RANI, versus a peer median of 45.4%.
RANI Competitors
Cash & Equivalents for RANI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TNXPTonix Pharmaceuticals Holding Corp.Mar 2026$185.47M USD+40.8%+20.0%71.9%
MOLNMolecular Partners AGMar 2026CHF 78.53M CHF-3.5%-2.0%89.9%
MISTMilestone Pharmaceuticals Inc.Mar 2026$71.32M USD+58.2%+112.3%36.8%
IPHAInnate Pharma S.A.Dec 2025€28.08M EUR-57.7%-30.7%44.8%
SGMOSangamo Therapeutics, Inc.Mar 2026$27.59M USD+9.6%-40.7%46.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$26.05M USD+37.8%+18.8%18.0%
ELTXElicio Therapeutics, Inc.Mar 2026$14.95M USD-18.5%+33.5%65.9%
RANIRani Therapeutics Holdings, Inc.Mar 2026$9.64M USD-4.6%-11.7%18.6%
CRDFCardiff Oncology, Inc.Mar 2026$8.54M USD-64.5%+2.2%17.4%
Peer median (excluding RANI) —+3.0%+10.5%45.4%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.45M27.01M5.86M3.76M18.62M
Short-term Investments071.48M42.68M23.88M31.09M
Net Receivables00200K428K2.04M
Inventory00000
Other Current Assets0500K800K1.68M1.57M
Total Current Assets119.6M100.92M50.85M29.74M53.32M
Property, Plant & Equipment (Net)4.61M7.1M6.82M6.64M5.05M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00246K246K246K
Total Non-current Assets4.61M7.1M7.07M6.89M5.3M
Total Assets124.21M108.03M57.92M36.63M58.62M
Account Payables1.08M1.46M648K1.36M309K
Short-term Debt004.9M15M0
Tax Payables00000
Deferred Revenue001.21M06.83M
Other Current Liabilities398K591K202K283K46K
Total Current Liabilities2.64M4.82M7.99M19.89M12.67M
Long-term Debt029.15M24.48M9.61M2.73M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.71M
Other Non-current Liabilities00000
Total Non-current Liabilities029.21M24.48M13.25M4.44M
Total Liabilities2.64M34.02M32.47M33.14M17.11M
Common Stock5K5K5K5K11K
Retained Earnings(8.33M)(38.92M)(72.89M)(102.91M)(132.58M)
Accumulated OCI(0)(73K)(12K)5K1K
Other Stockholders Equity(2)0000
Minority Interest74.16M37.15M12.58M1.5M8.5M
Total Equity121.57M74M25.44M3.49M41.51M
Total Debt030.21M30.1M29.71M4.32M
Net Debt(117.45M)3.21M24.24M25.95M(14.3M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.